Cowen began coverage on shares of Krystal Biotech (NASDAQ:KRYS) in a research report sent to investors on Wednesday, MarketBeat reports. The brokerage issued an outperform rating on the stock.

A number of other research analysts have also recently commented on the company. Zacks Investment Research raised Krystal Biotech from a hold rating to a buy rating and set a $26.00 target price on the stock in a research note on Tuesday. HC Wainwright reissued a buy rating and issued a $32.00 target price on shares of Krystal Biotech in a research note on Monday, November 5th. William Blair reissued a buy rating on shares of Krystal Biotech in a research note on Monday, November 5th. Cantor Fitzgerald reissued a buy rating and issued a $35.00 target price on shares of Krystal Biotech in a research note on Monday, October 15th. Finally, ValuEngine raised Krystal Biotech from a hold rating to a buy rating in a research note on Friday, September 21st. Eight equities research analysts have rated the stock with a buy rating, Krystal Biotech currently has a consensus rating of Buy and an average target price of $33.20.

KRYS traded down $0.48 during trading on Wednesday, reaching $23.31. The stock had a trading volume of 6,642 shares, compared to its average volume of 49,747. The stock has a market cap of $336.05 million, a PE ratio of -15.75 and a beta of -0.66. Krystal Biotech has a one year low of $8.03 and a one year high of $28.75.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 5th. The company reported ($0.26) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.26). As a group, equities research analysts predict that Krystal Biotech will post -0.95 EPS for the current year.

In other news, insider Krish S. Krishnan bought 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, October 18th. The shares were acquired at an average price of $20.00 per share, with a total value of $500,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 45.80% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Krystal Biotech by 13.1% during the third quarter. Vanguard Group Inc. now owns 173,478 shares of the company’s stock valued at $3,050,000 after buying an additional 20,100 shares during the last quarter. S Squared Technology LLC purchased a new stake in Krystal Biotech in the third quarter worth about $948,000. Renaissance Technologies LLC purchased a new stake in Krystal Biotech in the third quarter worth about $891,000. JPMorgan Chase & Co. lifted its holdings in Krystal Biotech by 69.0% in the third quarter. JPMorgan Chase & Co. now owns 36,133 shares of the company’s stock worth $635,000 after buying an additional 14,755 shares during the period. Finally, P.A.W. Capital Corp purchased a new position in shares of Krystal Biotech during the third quarter valued at approximately $527,000. 18.83% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.

Further Reading: What are the risks of holding treasury bonds?

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.